Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy-Reference-Cited by-同舟云学术

Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy

Published:2024-04-16 Issue: Volume: Page:
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Begré Lorin¹²^ORCID,Boyd Anders³⁴⁵⁶^ORCID,Plissonnier Marie-Laure⁷⁸^ORCID,Testoni Barbara⁷⁸^ORCID,Salazar-Vizcaya Luisa¹^ORCID,Suter-Riniker Franziska⁹^ORCID,Scholtès Caroline⁷¹⁰^ORCID,Béguelin Charles¹^ORCID,Rockstroh Jürgen K¹¹^ORCID,Günthard Huldrych F¹²¹³^ORCID,Calmy Alexandra¹⁴^ORCID,Cavassini Matthias¹⁵^ORCID,Hirsch Hans H¹⁶^ORCID,Schmid Patrick¹⁷^ORCID,Bernasconi Enos¹⁸^ORCID,Levrero Massimo⁷⁸¹⁹²⁰^ORCID,Wandeler Gilles¹^ORCID,Zoulim Fabien⁷⁸¹⁹²⁰^ORCID,Rauch Andri¹^ORCID, ,Abela I,Aebi-Popp K,Anagnostopoulos A,Battegay M,Bernasconi E,Braun D L,Bucher H C,Calmy A,Cavassini M,Ciuffi A,Dollenmaier G,Egger M,Elzi L,Fehr J,Fellay J,Furrer H,Fux C A,Günthard H F,Hachfeld A,Haerry D,Hasse B,Hirsch H H,Hoffmann M,Hösli I,Huber M,Jackson-Perry D,Kahlert C R,Keiser O,Klimkait T,Kouyos R D,Kovari H,Kusejko K,Labhardt N,Leuzinger K,Martinez de Tejada B,Marzolini C,Metzner K J,Müller N,Nemeth J,Nicca D,Notter J,Paioni P,Pantaleo G,Perreau M,Rauch A,Salazar-Vizcaya L,Schmid P,Speck R,Stöckle M,Tarr P,Trkola A,Wandeler G,Weisser M,Yerly S

Affiliation:

1. Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern , Switzerland

2. Graduate School for Health Sciences, University of Bern , Switzerland

3. Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam , The Netherlands

4. Stichting hiv monitoring Amsterdam , The Netherlands

5. Department ofInfectious Diseases, Amsterdam UMC location University of Amsterdam , The Netherlands

6. Department ofInfectious Diseases, Amsterdam Institute for Infection and Immunity , The Netherlands

7. Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286 , Lyon , France

8. IHU Lyon, Lyon Hepatology Institute , Lyon , France

9. Institute for Infectious Diseases, University of Bern , Switzerland

10. Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon , France

11. HIV Clinic, Department of Medicine I, University Hospital Bonn , Germany

12. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich , Switzerland

13. Institute of Medical Virology, University of Zurich , Switzerland

14. Division of Infectious Diseases, HIV Unit, Geneva University Hospitals, University of Geneva , Switzerland

15. Division of Infectious Diseases, Lausanne University Hospital, University of Lausanne , Switzerland

16. Transplantation and Clinical Virology, Department of Biomedicine, University of Basel , Switzerland

17. Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen , Switzerland

18. Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland , Lugano , Switzerland

19. University of Lyon, University Claude Bernard Lyon 1 (UCBL1) , Lyon , France

20. Department of Hepatology, Hospices Civils de Lyon , Lyon , France

Abstract

Abstract Background We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study. Methods We included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates. Results HBsAg loss occurred after a median of 4 years (IQR, 1–8). All participants with HBsAg loss achieved suppressed HBV DNA and undetectable HBV RNA preceding undetectable quantitative HBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After 2 years of tenofovir therapy, an HBV RNA decline ≥1 log10 copies/mL had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/mL had 91.0% sensitivity and 64.5% specificity. Conclusions HBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in persons with HIV. HBcrAg remained detectable in approximately 20% of persons with HBsAg loss and 50% of persons without HBsAg loss.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiae189/57567744/jiae189.pdf

Reference42 articles.

1. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis;Nikolopoulos;Clin Infect Dis,2009

2. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection;European Association for the Study of the Live;J Hepatol,2017

3. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis;Anderson;Clin Gastroenterol Hepatol,2021